{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma&page=33&q=advanced+melanoma", "query": { "q": "advanced melanoma", "condition": "Melanoma", "page": 33 }, "page_size": 10 }, "pagination": { "page": 33, "page_size": 10, "total_count": 832, "total_pages": 84, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma&page=34&q=advanced+melanoma&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma&page=32&q=advanced+melanoma&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T13:36:46.633Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01352884", "title": "Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "AMP-224", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2011-03", "completion_date": "2014-01", "has_results": false, "last_update_posted_date": "2016-09-05", "last_synced_at": "2026-10-16T13:36:46.633Z", "location_count": 4, "location_summary": "Detroit, Michigan • New York, New York • Huntersville, North Carolina + 1 more", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01352884" }, { "nct_id": "NCT01585415", "title": "Vemurafenib and White Blood Cell Therapy for Advanced Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Cancer", "Melanoma" ], "interventions": [ { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Young TIL", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "66 Years", "sex": "ALL", "summary": "18 Years to 66 Years" }, "enrollment_count": 12, "start_date": "2012-04-09", "completion_date": "2016-07-21", "has_results": false, "last_update_posted_date": "2019-11-21", "last_synced_at": "2026-10-16T13:36:46.633Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01585415" }, { "nct_id": "NCT05144698", "title": "RAPA-201 Therapy of Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Small Cell and Non-small Cell Lung Cancer", "Head and Neck Cancer", "Squamous Cell Carcinoma of Oral Cavity", "Squamous Cell Carcinoma of Larynx", "Squamous Cell Carcinoma of Nasopharynx", "Squamous Cell Carcinoma of Other Specified Sites of Skin", "Malignant Melanoma", "Esophageal Squamous Cell Carcinoma" ], "interventions": [ { "name": "RAPA-201 Rapamycin Resistant T Cells", "type": "BIOLOGICAL" }, { "name": "Chemotherapy Prior to RAPA-201 Therapy", "type": "DRUG" }, { "name": "Pembrolizumab (PD-1 Blocking Antibody)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Rapa Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2021-08-01", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-05-14", "last_synced_at": "2026-10-16T13:36:46.633Z", "location_count": 1, "location_summary": "Hackensack, New Jersey", "locations": [ { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05144698" }, { "nct_id": "NCT04752826", "title": "BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignancies", "Ovarian Cancer", "T-cell Lymphoma", "Melanoma" ], "interventions": [ { "name": "BI-1808", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection", "type": "DRUG" }, { "name": "Paclitaxel 80 mg/m2 weekly", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioInvent International AB", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2021-01-25", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-16T13:36:46.633Z", "location_count": 3, "location_summary": "Duarte, California • New York, New York • Philadelphia, Pennsylvania", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04752826" }, { "nct_id": "NCT06580938", "title": "A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer", "Bladder Cancer", "Renal Cell Carcinoma", "Melanoma", "Head and Neck Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "PF-07921585", "type": "BIOLOGICAL" }, { "name": "Sasanlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2024-11-11", "completion_date": "2025-07-14", "has_results": false, "last_update_posted_date": "2026-03-23", "last_synced_at": "2026-10-16T13:36:46.633Z", "location_count": 9, "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 4 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06580938" }, { "nct_id": "NCT04130516", "title": "Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER", "type": "DRUG" }, { "name": "Pembrolizumab - anti-PD-1 antibody", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Linnaeus Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2019-10-21", "completion_date": "2026-08-15", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-10-16T13:36:46.633Z", "location_count": 10, "location_summary": "Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04130516" }, { "nct_id": "NCT01727076", "title": "Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Recurrent Head and Neck Carcinoma", "Recurrent Non-Small Cell Lung Carcinoma", "Recurrent Renal Cell Carcinoma", "Recurrent Skin Carcinoma", "Stage III Renal Cell Cancer", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIA Non-Small Cell Lung Cancer AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIB Non-Small Cell Lung Cancer AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Stage IV Non-Small Cell Lung Cancer AJCC v7", "Stage IV Renal Cell Cancer" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Recombinant Human Interleukin-15", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 20, "start_date": "2013-02-15", "completion_date": "2016-06-30", "has_results": false, "last_update_posted_date": "2017-09-15", "last_synced_at": "2026-10-16T13:36:46.633Z", "location_count": 5, "location_summary": "Palo Alto, California • Bethesda, Maryland • Minneapolis, Minnesota + 2 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Seattle", "state": "Washington" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01727076" }, { "nct_id": "NCT01519427", "title": "Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage IIIA Melanoma", "Stage IIIB Melanoma", "Stage IIIC Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "Akt inhibitor MK2206", "type": "DRUG" }, { "name": "selumetinib", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2012-01", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2014-06-18", "last_synced_at": "2026-10-16T13:36:46.633Z", "location_count": 4, "location_summary": "Atlanta, Georgia • New Brunswick, New Jersey • Nashville, Tennessee + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01519427" }, { "nct_id": "NCT00375245", "title": "Rapamycin With Grapefruit Juice for Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumors", "Neoplasm Metastasis" ], "interventions": [ { "name": "Rapamycin (sirolimus)", "type": "DRUG" }, { "name": "Grapefruit Juice", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2006-09", "completion_date": "2012-05", "has_results": false, "last_update_posted_date": "2014-01-17", "last_synced_at": "2026-10-16T13:36:46.633Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00375245" }, { "nct_id": "NCT04375527", "title": "Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC V8", "Clinical Stage IV Cutaneous Melanoma AJCC V8", "Locally Advanced Cutaneous Melanoma", "Metastatic Cutaneous Melanoma", "Pathologic Stage III Cutaneous Melanoma AJCC V8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC V8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC V8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC V8", "Pathologic Stage IIID Cutaneous Melanoma AJCC V8", "Pathologic Stage IV Cutaneous Melanoma AJCC V8", "Unresectable Cutaneous Melanoma" ], "interventions": [ { "name": "Binimetinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2020-12-03", "completion_date": "2024-11-22", "has_results": false, "last_update_posted_date": "2024-12-04", "last_synced_at": "2026-10-16T13:36:46.633Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04375527" } ] }